Third Line Therapy News Today

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Data Bridge Market Researchs latest report, "Self-injections Market" provides a thorough analysis of growth strategies, drivers, opportunities, key segments,

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.

Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer 1 non-small cell lung cancer 2,3 help 1 beta (IL-1ß) in pro-tumor inflammation i n lung cancer, with multiple clinical trials investigating canakinumab in 2 -5 Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1b...